Sling Therapeutics Launches with $35M Series A Financing to Develop Oral Small Molecule for Thyroid Eye Disease - read this article along with other careers information, tips and advice on BioSpace
Equipped with $35 million in financing, a new Ann Arbor life sciences company is out of "stealth mode" and working to create a drug to treat a debilitating eye disorder. Sling Therapeutics Inc. — comprised of various biotech industry veterans, many of whom worked in roles at the now defunct…
/PRNewswire/ Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid.